glp-1 epilepsy The Hidden Genome of Treatment: Lessons for Pharmacogenomics from Agonists GLP-1 receptor agonists in people

Sandoz has been told its submission doesn't yet meet requirements and needs additional data pushing its expected launch from early 2026 to Q3 2026 at the earliest

In the cohort not using CPAP at baseline, the mean AHI dropped by approximately 27 events per hour

One study on mice showed that GLP-1 drugs increased the bowel size and height of the mucosa in the small intestines

When excessive urination and thirst is present, it may be caused by an inability to concentrate urine eg diabetes insipidus, or an expected side effect of diuretics such as caffeine or 'water pills', the latter which are commonly used for hypertension (raised blood pressure), or heart failure

The very short plasmatic half-life represents a major limitation for the possible use of GLP-1 in the clinical setting